미국의 혈중 케톤 측정기 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 최종 용도별, 부문별 예측(2025-2033년)

U.S. Blood Ketone Meter Market Summary

The U.S. blood ketone meter market size was estimated at USD 106.1 million in 2024 and is projected to reach USD 115.1 million by 2033, growing at a CAGR of 0.9% from 2025 to 2033. Some of the factors contributing to market growth include the increasing prevalence of diabetes, growing health awareness among consumers and rising adoption of ketogenic and low-carbohydrate diets.

The growth is driven by increasing interest in metabolic health management, particularly within the keto diet community and among people who need to monitor Blood ketone meters are used to monitor ketone levels for managing Type 1 Diabetes (T1D), tracking nutritional ketosis in ketogenic diets, and supporting the treatment of neurological conditions such as epilepsy. A 2023 study titled "Point-of-Care Capillary Blood Ketone Measurements and the Prediction of Future Ketoacidosis Risk in Type 1 Diabetes" investigated whether routine point-of-care capillary blood ketone measurements in fasted, symptom-free individuals with T1D could predict future DKA events.

The findings showed that routine capillary ketone monitoring can help identify individuals at elevated risk of future DKA, highlighting the potential value of emerging technologies such as Continuous Ketone Monitoring (CKM) for early intervention and prevention. With the growing awareness of DKAprevention, such evidence will likely broaden the adoption and expansion of the U.S. blood ketone meter market.

The U.S. blood ketone meter industry is shaped by evolving care delivery models and payer policy reforms. The rise of telehealth, boosted significantly by the COVID-19 pandemic, has made diabetes management more accessible by enabling remote consultations, real-time data sharing, and timely treatment adjustments. This shift supports more consistent use of monitoring tools such as blood ketone meters, especially for patients managing T1D or adhering to ketogenic therapies. In 2024, approximately 20,000 children and adolescents under the age of 20 in the U.S. were newly diagnosed with T1D. This increase is driven by inherited risk, environmental factors, and changes in early-life habits (such as diet and infections).

The MDPI 2025 study titled "Severe Diabetic Ketoacidosis in Children with Type 1 Diabetes" highlighted key findings on ketone monitoring. The study found that blood ketone testing was more effective than urine ketone testing in early DKA detection and management.

U.S. Blood Ketone Meter Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. blood ketone meter market report based on type, application, and end use:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Blood Ketone Monitoring
  • Blood Glucose and Ketone Monitoring
  • Consumables
• Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Humans
  • Veterinary
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Diagnostic Centers
  • Home Care Settings
  • Other

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. Application
  • 1.2.3. End use
  • 1.2.4. Gender
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type Outlook
  • 2.2.2. Application Outlook
  • 2.2.3. End use Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Blood Ketone Meter Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. U.S. Blood Ketone Meter Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political Landscape
    • 3.3.2.2. Technological Landscape
    • 3.3.2.3. Economic Landscape
• 3.4. U.S. Blood Ketone Meter Market: Pipeline Analysis

Chapter 4. U.S. Blood Ketone Meter Market: Type Estimates & Trend Analysis

• 4.1. Type Segment Dashboard
• 4.2. U.S. Blood Ketone Meter Market: Type Movement Analysis
• 4.3. U.S. Blood Ketone Meter Market Size & Trend Analysis, by type, 2021 - 2033 (USD Million)
• 4.4. Blood Ketone Monitoring
  • 4.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 4.5. Blood Glucose and Ketone Monitoring
  • 4.5.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 4.6. Consumables
  • 4.6.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)

Chapter 5. U.S. Blood Ketone Meter Market: Application Estimates & Trend Analysis

• 5.1. Application Segment Dashboard
• 5.2. U.S. Blood Ketone Meter Market: Application Movement Analysis
• 5.3. U.S. Blood Ketone Meter Market Size & Trend Analysis, by Application, 2021 - 2033 (USD Million)
• 5.4. Humans
  • 5.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 5.5. Veterinary
  • 5.5.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)

Chapter 6. U.S. Blood Ketone Meter Market: End Use Estimates & Trend Analysis

• 6.1. End use Segment Dashboard
• 6.2. U.S. Blood Ketone Meter Market: End Use Movement Analysis
• 6.3. U.S. Blood Ketone Meter Market Size & Trend Analysis, by End Use, 2021 - 2033 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Market Estimates and Forecasts 2021 - 2033 (USD million)
• 6.5. Diagnostic Centers
  • 6.5.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 6.6. Home Care Settings
  • 6.6.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, by Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. Key company heat map analysis, 2024
• 7.4. Company Profiles
  • 7.4.1. Abbott
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Type benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Apex Biotechnology Corp.
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Type benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. TaiDoc Technology Corporation
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Type benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. EKF Diagnostic Holdings plc.
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Type benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. Nova Biomedical
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Type benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Keto-Mojo
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Type benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. ForaCare, Inc.
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Type benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. Nipro
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Type benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. I-SENS, Inc
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Type benchmarking
    • 7.4.9.4. Strategic initiatives